I
n developing countries, it is estimated that 56% of pregnant women have anemia (compared with 18% in developed countries) and that approximately 20% of maternal deaths are either directly or indirectly related to anemia. 1, 2 The causes of anemia during pregnancy are multifactorial, but one of the primary causes in developing countries is infection with hookworms. The age-prevalence and age-intensity curves of hookworm infection reach their peak in young adulthood and remain at this level throughout life. 3 Pregnant women therefore constitute a high-risk group for anemia and hookworm infection. It has been estimated that one-third of all pregnant women in developing countries are infected with hookworms. 4 Anemia has important adverse consequences on the health of both the pregnant woman and the fetus. 5 Deworming during pregnancy is therefore considered as an effective tool in reducing anemia in areas where hookworm prevalence exceeds 20% to 30%. 6, 7 The World Health Organization (WHO) recommends any of the following 4 drugs for the treatment of hookworm infection in pregnancy: albendazole, levamisole, mebendazole and pyrantel. 7 These drugs, administered after the first trimester, have been found to be safe and effective, having few and minor, if any, side effects. 2, 8, 9 Because of the ease of use of their single-dose format, the benzimidazoles (albendazole and mebendazole) are the drugs most widely used in helminth control programs targeted to school-aged children and pregnant women. 10 -12 Despite the recognized benefits of deworming, it is possible that fear of adverse birth outcomes has limited its inclusion in routine antenatal care.
To date, 4 studies have examined adverse birth outcomes after use of albendazole or mebendazole during pregnancy (Table 1) . Three were observational studies examining mebendazole 10, 13, 14 and one was a randomized, controlled trial of albendazole. 15 None of these studies found significantly more adverse outcomes in the benzimidazole group compared with the comparison group. However, because of limitations in study design and methodology (eg, small sample sizes, unknown or nonstandard dosages, possibility of information and selection biases) and a lack of detail in the ascertainment or reporting of the adverse outcomes, a new and rigorous evaluation was warranted.
We therefore report on the adverse birth outcomes from a large double-blind, placebo-controlled, randomized trial we conducted in Iquitos, Peru, a highly hookworm-endemic area. Baseline data confirmed a high prevalence of hookworm infection (47.2%) in the pregnant women participating in the trial, 16 thereby meeting the WHO threshold of over 20% to 30% for routine deworming in antenatal care.
METHODS
Details of the double-blind, randomized, controlled trial comparing iron plus mebendazole versus iron plus placebo appear in the international trial registry ISRCTN08446014. This trial received ethics approval from the McGill University Health Centre in Montreal, Canada, the Ministerio de Salud in Iquitos, Peru, and the Universidad Cayetano Peruana Heredia in Lima, Peru; and satisfied all ethics questions of the funding agency (The Canadian Institutes of Health Research). All participating women signed an informed consent form. Briefly, between April and November 2003, a total of 1042 pregnant women were recruited in their second trimester and randomized to receive either a single 500-mg dose of mebendazole (Nemasole) or placebo (Jansen-Cilag Pharmaceutical ͓Brazil͔) together with a 30-day supply of iron supplements (ferrous sulfate, 60 mg elemental iron; PharmaScience, Canada). After randomization, women in both groups received 30-day supplies of iron supplements throughout their pregnancy. The mebendazole and placebo were single-dose tablets of 500 mg and were administered by the interviewer to the women at the time of the initial interview. Interviewers were blind to treatment assignment. Interviewers were qualified nurse midwives or "obstetrices" with membership in the "Colegio de Obstetrices de Loreto" whose university-based training included 5 years of nursing specializing in obstetrics. Women were eligible to participate in the trial if they were older than 18 years of age, were in their second trimester of pregnancy, lived in a periurban or rural area (did not have water or sanitation facilities in the home), had not taken any anthelminthic treatment in the previous 6 months and gave consent.
Gestational age was estimated from information provided by the woman on date of last menstrual period and on measurement of fundal height as ascertained by the obstetriz. Birth outcome and birth weight were recorded at the hospital or the woman's home (in the case of a domiciliary birth). Birth weight was measured using digital stationary or portable scales (Secacorp) that were supplied by the project. In the case of a domiciliary birth, the baby was observed by the research obstetriz within 48 hours of birth for assessment of clinical outcome. Adverse birth outcomes were recorded as miscarriage, malformation, stillbirth, early neonatal death (death at Ͻ7 days) and premature birth (birth Ͻ37 weeks' gestation). The attending physician and nurses at delivery were blind to the treatment assignment of the woman. Details on the type of malformation and cause of early neonatal death were obtained from medical charts in the study hospitals. In all cases of adverse birth outcomes, the diagnosis was confirmed by the hospital neonatologist.
Twins were excluded from all analyses. A comparison of the proportions of adverse outcomes in the 2 groups was tested using the 2 test. Perinatal mortality was calculated as follows: (number of stillbirths ϩ number of early neonatal deaths)/1000 births.
RESULTS
Mebendazole and placebo were administered at an average gestational age of 20.44 Ϯ 2.61 and 20.35 Ϯ 2.56 weeks, respectively. There was no reported use of anthelminthic medication other than that provided by the trial. There were no differences between the 2 groups in terms of age schooling: 75.2% versus 73.7%) in addition to other sociodemographic variables. Moreover, hemoglobin levels at baseline were similar in both groups (11.05 g/dL Ϯ 1.10 versus 11.01 g/dL Ϯ 1.06) (data not shown). There were 22 outcomes excluded in the mebendazole group (n ϭ 522): 3 were twins, 17 were lost to follow up and 2 had missing birth weight and outcome information. There were 24 outcomes excluded in the placebo group (n ϭ 520): 2 were twins, 19 were lost to follow up and 3 had missing birth weight and outcome information. Overall, loss to follow up and incomplete information accounted for 3.95% (41 of 1037) of the total population, excluding twins (ie, 3.7% and 4.2% in the mebendazole and placebo groups, respectively). Birth weight outcomes (mean birth weight, low birth weight and very low birth weight) are detailed in Larocque et al (unpublished data). There was a total of 28 (5.60%) adverse birth outcomes in the mebendazole group compared with 31 (6.25%) in the placebo group (Table 2 ). This difference was not statistically significant (P ϭ 0.664). Although there were a greater number of stillbirths in the mebendazole group (8 versus 4), there were fewer early neonatal deaths (3 versus 6). The number of malformations in the mebendazole group was lower than in the placebo group (7 versus 8). The respective proportions of malformations were 1.40% (7 of 500) and 1.61% (8 of 496), a difference that was not statistically significant (P ϭ 0.783). No clinically significant difference was found between the 2 groups in terms of miscarriages (2 versus 3) (P ϭ 0.647). None of these differences was considered clinically significant. Details of the type of malformations are given in Table 3 .
The perinatal mortality rate was 22 per 1000 births in the mebendazole group compared with 20.2 per 1000 births in the placebo group. These rates were not found to be either clinically or statistically significantly different (P ϭ 0.840).
Issues of compliance are not of concern here because both the mebendazole and the placebo were administered as single 500-mg tablets and consumption was directly observed by the research obstetrices. Daily compliance with the iron supplements was difficult to ascertain, but it was considered to be similar in the 2 groups based on attendance at follow-up visits and self-reporting of consumption at the time of provision of monthly refills.
DISCUSSION
These data on adverse birth outcomes were obtained from the largest placebo-controlled, randomized trial of a benzimidazole administered during pregnancy. The perinatal mortality rates in this study were similar to those reported for the Americas in 1999 (ie, 22 per 1000 livebirths), 17 whereas our malformation rates were lower (ie, 1.5% versus 2-3% 18 ). Loss to follow up was minimal and equivalent in the 2 groups, further substantiating the internal validity of the results and the use of univariate statistical testing.
Our results provide rigorous evidence and additional support to those of previous studies that have reported no additional important adverse effects of either mebendazole or albendazole on birth outcomes after use during pregnancy after the first trimester.
11,13-15 National governments, healthcare practitioners and helminth control program managers should be confident in the routine inclusion of these anthelminthics in antenatal care programs in areas where hookworm infection meets the threshold prevalence set by WHO (ie, Ͼ20 -30%).
Future research from randomized, controlled trials on this issue would further strengthen the evidence. In particular, it would be helpful to understand if a similar finding holds for each of the 4 WHO-recommended deworming drugs in areas where the intensity of hookworm infection varies and in areas where the species (or ratios between the species) of hookworm differ (ie, Necator americanus versus Ancylostoma duodenale). Promotion of deworming in pregnant women is warranted, especially when hookworm prevalence or the proportion of heavy-intensity hookworm infection greatly exceeds the threshold. To date, only Sri Lanka and Nepal 
